Absea Biotech

Transforming protein engineering on a global scale. Founded in 2020, Absea is one of the fastest-growing biotech companies, with over 250 employees worldwide. Our cutting-edge platform enables rapid development of soluble proteins and monoclonal antibodies, supporting up to 1,000 new projects each month. In partnership with leaders in life sciences, we have built a synthetic library of 14,000 soluble proteins, covering 70% of the human proteome, and we continue to expand our portfolio .Our validated monoclonal antibodies are designed for diverse applications and are ready for broad market supply. From our Innovation Center in Berlin, Manufacturing Centers in China, to our Commercialization Center in the Bay Area, we support protein scientists and industry partners engaged in AI-driven protein design, diagnostics, and drug development. At Absea, we strive to be the long-term partner of choice for the world’s leading labs, companies, and service providers. Let’s engineer the future together. Connect with us to explore how Absea can power your research and discovery.